{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:50:12Z","timestamp":1791557412165,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41409-026-02982-2","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:01:06Z","timestamp":1784739666000},"page":"1308-1315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation in sickle cell disease: a narrative review of safety, engraftment, and graft-versus-host-disease outcomes in adults and high-risk populations"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9203-7446","authenticated-orcid":false,"given":"Ghada","family":"Elgohary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Alsharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4498-3865","authenticated-orcid":false,"given":"Riad","family":"El Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8978-7994","authenticated-orcid":false,"given":"Chokri","family":"Mohammed Ben Lamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3942-7370","authenticated-orcid":false,"given":"Mahmoud","family":"Al Jurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"2982_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.31486\/toj.18.0044","volume":"19","author":"K Khemani","year":"2019","unstructured":"Khemani K, Katoch D, Krishnamurti L. Curative therapies for sickle cell disease. Ochsner J. 2019;19:131\u2013137.","journal-title":"Ochsner J"},{"key":"2982_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1053\/j.seminhematol.2018.04.011","volume":"55","author":"GMT Guilcher","year":"2018","unstructured":"Guilcher GMT, Truong TH, Saraf SL, Joseph JJ, Rondelli D, Hsieh MM. Curative therapies: allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease. Semin Hematol 2018;55:87\u201393. Elsevier.","journal-title":"Semin Hematol"},{"key":"2982_CR3","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.3390\/jcm8111997","volume":"8","author":"E Limerick","year":"2019","unstructured":"Limerick E, Fitzhugh C. Choice of donor source and conditioning regimen for hematopoietic stem cell transplantation in sickle cell disease. J Clin Med. 2019;8:1997.","journal-title":"J Clin Med"},{"key":"2982_CR4","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.bbmt.2016.04.025","volume":"22","author":"LM Madden","year":"2016","unstructured":"Madden LM, Hayashi RJ, Chan KW, Pulsipher MA, Douglas D, Hale GA, et al. Long-term follow-up after reduced-intensity conditioning and stem cell transplantation for childhood nonmalignant disorders. Biol Blood Marrow Transpl. 2016;22:1467\u201372.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2982_CR5","first-page":"273","volume":"2011","author":"S Shenoy","year":"2011","unstructured":"Shenoy S. Hematopoietic stem cell transplantation for sickle cell disease: current practice and emerging trends. Hematol 2010, Am Soc Hematol Educ Program Book. 2011;2011:273\u20139.","journal-title":"Hematol 2010, Am Soc Hematol Educ Program Book"},{"key":"2982_CR6","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1016\/S2352-3026(19)30154-1","volume":"6","author":"M Eapen","year":"2019","unstructured":"Eapen M, Brazauskas R, Walters MC, Bernaudin F, Bo-Subait K, Fitzhugh CD, et al. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematol. 2019;6:e585\u2013e596.","journal-title":"Lancet Haematol"},{"key":"2982_CR7","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ajh.26656","volume":"97","author":"N Dhedin","year":"2022","unstructured":"Dhedin N, Chevillon F, Castelle M, Lavoipi\u00e8re V, Vasseur L, Dalle J-H, et al. HLA-matched related donor hematopoietic stem cell transplantation is a suitable treatment in adolescents and adults with sickle cell disease: Comparison of myeloablative and non-myeloablative approaches. Am J Hematol. 2022;97:E359\u2013E362.","journal-title":"Am J Hematol"},{"key":"2982_CR8","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.3390\/jcm11092318","volume":"11","author":"RS Nickel","year":"2022","unstructured":"Nickel RS, Maher JY, Hsieh MH, Davis MF, Hsieh MM, Pecker LH. Fertility after curative therapy for sickle cell disease: a comprehensive review to guide care. J Clin Med. 2022;11:2318.","journal-title":"J Clin Med"},{"key":"2982_CR9","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1182\/blood-2024-200303","volume":"144","author":"A Nasiri","year":"2024","unstructured":"Nasiri A, Samarkandi S, Alasbali R, Alahmadi A, Nassar M, Alfattah H, et al. Steroid Pre-Busulfan Based Reduced-Intensity Conditioning in Matched Related Hematopoietic Stem Cell Transplantation: Outcomes in Young and Adult Sickle Cell Disease Patients. Blood. 2024;144:1142.","journal-title":"Blood"},{"key":"2982_CR10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.bbmt.2017.10.030","volume":"24","author":"HG Rangarajan","year":"2018","unstructured":"Rangarajan HG, Abu-Arja R, Pai V, Guilcher GM, Soni S. Outcomes of unrelated donor stem cell transplantion with post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in patients with severe sickle cell disease. Biol Blood Marrow Transpl. 2018;24:413\u20137.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2982_CR11","first-page":"4285","volume":"120","author":"J Bola\u00f1os-Meade","year":"2012","unstructured":"Bola\u00f1os-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood J Am Soc Hematol. 2012;120:4285\u201391.","journal-title":"Blood J Am Soc Hematol"},{"key":"2982_CR12","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.bbmt.2007.08.050","volume":"13","author":"ME Horwitz","year":"2007","unstructured":"Horwitz ME, Spasojevic I, Morris A, Telen M, Essell J, Gasparetto C, et al. Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics. Biol Blood Marrow Transpl. 2007;13:1422\u20136.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2982_CR13","first-page":"1946","volume":"130","author":"CD Fitzhugh","year":"2017","unstructured":"Fitzhugh CD, Cordes S, Taylor T, Coles W, Roskom K, Link M, et al. At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT. Blood J Am Soc Hematol. 2017;130:1946\u20138.","journal-title":"Blood J Am Soc Hematol"},{"key":"2982_CR14","doi-asserted-by":"publisher","first-page":"EVIDoa2400192","DOI":"10.1056\/EVIDoa2400192","volume":"4","author":"AA Kassim","year":"2025","unstructured":"Kassim AA, Walters MC, Eapen M, Smith M, Logan BR, Solh M, et al. Haploidentical bone marrow transplantation for sickle cell disease. NEJM Evid. 2025;4:EVIDoa2400192.","journal-title":"NEJM Evid"},{"key":"2982_CR15","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1016\/j.bbmt.2017.08.038","volume":"23","author":"A Abraham","year":"2017","unstructured":"Abraham A, Hsieh M, Eapen M, Fitzhugh C, Carreras J, Keesler D, et al. Relationship between mixed donor\u2013recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transpl. 2017;23:2178\u201383.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2982_CR16","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/17474086.2024.2423368","volume":"17","author":"M Goldenberg","year":"2024","unstructured":"Goldenberg M, Lanzkron S, Pecker LH. Late effects of hemopoietic stem cell transplant for sickle cell disease: monitoring and management. Expert Rev Hematol. 2024;17:891\u2013905.","journal-title":"Expert Rev Hematol"},{"key":"2982_CR17","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1182\/hematology.2022000373","volume":"2022","author":"R Chakravarthy","year":"2022","unstructured":"Chakravarthy R, Friedman DL. Long-term health outcomes following curative therapies for sickle cell disease. Hematology. 2022;2022:272\u20136.","journal-title":"Hematology"},{"key":"2982_CR18","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/FTD.0b013e3181efb3d2","volume":"32","author":"E Wieland","year":"2010","unstructured":"Wieland E, Olbricht CJ, S\u00fcsal C, Gurragchaa P, B\u00f6hler T, Israeli M, et al. Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit. 2010;32:560\u201372.","journal-title":"Ther Drug Monit"},{"key":"2982_CR19","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/ajh.25401","volume":"94","author":"L Krishnamurti","year":"2019","unstructured":"Krishnamurti L, Neuberg DS, Sullivan KM, Kamani NR, Abraham A, Campigotto F, et al. Bone marrow transplantation for adolescents and young adults with sickle cell disease: results of a prospective multicenter pilot study. Am J Hematol. 2019;94:446\u201354.","journal-title":"Am J Hematol"},{"key":"2982_CR20","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40273-022-01234-7","volume":"41","author":"SP Gavan","year":"2023","unstructured":"Gavan SP, Wright SJ, Thistlethwaite F, Payne K. Capturing the impact of constraints on the cost-effectiveness of cell and gene therapies: a systematic review. Pharmacoeconomics. 2023;41:675\u201392.","journal-title":"Pharmacoeconomics"},{"key":"2982_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jcyt.2024.09.001","volume":"27","author":"JH Oved","year":"2025","unstructured":"Oved JH, Russell A, DeZern A, Prockop SE, Bonfim C, Sharma A, et al. The role of the conditioning regimen for autologous and ex vivo genetically modified hematopoietic stem cell-based therapies: recommendations from the ISCT stem cell engineering committee. Cytotherapy. 2025;27:78\u201384.","journal-title":"Cytotherapy"},{"key":"2982_CR22","first-page":"16","volume":"62","author":"BP Sim\u00f5es","year":"2016","unstructured":"Sim\u00f5es BP, Pieroni F, Costa T, Barros GN, Darrigo JrG, Grecco CS, et al. Allogenic bone narrow transplantation in sickle-cell diseases. Rev da Assoc\u00e7\u00e3o M\u00e9dica Brasileira. 2016;62:16\u201322.","journal-title":"Rev da Assoc\u00e7\u00e3o M\u00e9dica Brasileira"},{"key":"2982_CR23","doi-asserted-by":"crossref","unstructured":"Bernaudin F, Pondarr\u00e9 C, Galambrun C, Thuret I Allogeneic\/matched related transplantation for \u03b2-thalassemia and sickle cell anemia. In: Gene and Cell Therapies for Beta-Globinopathies. Springer, (2017), pp 89-122.","DOI":"10.1007\/978-1-4939-7299-9_4"},{"key":"2982_CR24","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1016\/S2352-3026(17)30196-5","volume":"4","author":"ES Allen","year":"2017","unstructured":"Allen ES, Srivastava K, Hsieh MM, Fitzhugh CD, Klein HG, Tisdale JF, et al. Immunohaematological complications in patients with sickle cell disease after haemopoietic progenitor cell transplantation: a prospective, single-centre, observational study. Lancet Haematol. 2017;4:e553\u2013e561.","journal-title":"Lancet Haematol"},{"key":"2982_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/phar.2641","volume":"42","author":"D Furstenau","year":"2022","unstructured":"Furstenau D, Peer CJ, Hughes TE, Uchida N, Tisdale J, Hall OM, et al. Alemtuzumab clearance, lymphocyte count, and T-cell chimerism after hematopoietic stem cell transplant in sickle cell disease. Pharmacotherapy: J Hum Pharmacol Drug Ther. 2022;42:14\u201322.","journal-title":"Pharmacotherapy: J Hum Pharmacol Drug Ther"},{"key":"2982_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720932038","volume":"11","author":"J-H Yoon","year":"2020","unstructured":"Yoon J-H, Park S-S, Min GJ, Park S, Lee S-E, Cho B-S, et al. Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis. Ther Adv Hematol. 2020;11:2040620720932038.","journal-title":"Ther Adv Hematol"},{"key":"2982_CR27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/ejh.13455","volume":"105","author":"SH Shin","year":"2020","unstructured":"Shin SH, Park SS, Park S, Jeon YW, Yoon JH, Yahng SA, et al. Non-myeloablative matched sibling stem cell transplantation with the optional reinforced stem cell infusion for patients with hemoglobinopathies. Eur J Haematol. 2020;105:387\u201398.","journal-title":"Eur J Haematol"},{"key":"2982_CR28","doi-asserted-by":"publisher","first-page":"a011825","DOI":"10.1101\/cshperspect.a011825","volume":"2","author":"G Lucarelli","year":"2012","unstructured":"Lucarelli G, Isgr\u00f2 A, Sodani P, Gaziev J. Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. Cold Spring Harb Perspect Med. 2012;2:a011825.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2982_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70100","volume":"9","author":"E Dovern","year":"2025","unstructured":"Dovern E, Nijland SJ, Braamse AM, van Muilekom MM, Suijk EM, Hoogendoorn GM, et al. Changes in the quality of life of adults with sickle cell disease following allogeneic stem cell transplantation: a mixed-methods, prospective cohort study. HemaSphere. 2025;9:e70100.","journal-title":"HemaSphere"},{"key":"2982_CR30","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41409-022-01749-9","volume":"57","author":"HG Rangarajan","year":"2022","unstructured":"Rangarajan HG, Crowell SA, Towerman AS, Shenoy SS. CD34-selected stem cell boost as therapy for late graft rejection following allogeneic transplantation for sickle cell disease. Bone Marrow Transplant. 2022;57:1592\u20134.","journal-title":"Bone Marrow Transplant"},{"key":"2982_CR31","doi-asserted-by":"crossref","unstructured":"Ngwube A, Shenoy S Unrelated donor hematopoietic stem cell transplantation for sickle cell disease. In: Sickle Cell Disease and Hematopoietic Stem Cell Transplantation. Springer, 2017, pp 271\u201381.","DOI":"10.1007\/978-3-319-62328-3_13"},{"key":"2982_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.757279","volume":"12","author":"DK Bhat","year":"2021","unstructured":"Bhat DK, Olkhanud PB, Gangaplara A, Seifuddin F, Pirooznia M, Biancotto A, et al. Early myeloid derived suppressor cells (eMDSCs) are associated with high donor myeloid chimerism following haploidentical HSCT for sickle cell disease. Front Immunol. 2021;12:757279.","journal-title":"Front Immunol"},{"key":"2982_CR33","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.jcyt.2019.10.003","volume":"21","author":"LN Raines","year":"2019","unstructured":"Raines LN, Hsieh MM, Nassehi T, Drysdale CM, Tisdale JF, Uchida N. Ex vivo immunological evaluation of stable mixed chimeric patients after matched related donor allogeneic transplantation in sickle cell disease. Cytotherapy. 2019;21:1206\u201315.","journal-title":"Cytotherapy"},{"key":"2982_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3324\/haematol.2018.213207","volume":"105","author":"F Bernaudin","year":"2019","unstructured":"Bernaudin F, Dalle J-H, Bories D, de Latour RP, Robin M, Bertrand Y, et al. Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France. Haematologica. 2019;105:91.","journal-title":"Haematologica"},{"key":"2982_CR35","doi-asserted-by":"publisher","first-page":"S246","DOI":"10.1016\/j.ijrobp.2019.06.364","volume":"105","author":"M Koshy","year":"2019","unstructured":"Koshy M, Son C, Spiotto M, Rondelli D, Saraf S. Prospective evaluation of total body radiation in the conditioning regimen of patients undergoing allogeneic stem cell transplantation for sickle cell disease. Int J Radiat Oncol, Biol, Phys. 2019;105:S246\u2013S247.","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"key":"2982_CR36","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1182\/bloodadvances.2018024844","volume":"2","author":"S Chhabra","year":"2018","unstructured":"Chhabra S, Ahn KW, Hu Z-H, Jain S, Assal A, Cerny J, et al. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Adv. 2018;2:2922\u201336.","journal-title":"Blood Adv"},{"key":"2982_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2020-139348","volume":"136","author":"M Alzahrani","year":"2020","unstructured":"Alzahrani M, Alahmari B, Alaskar A, Hejazi A, Gmati GE, Abuelgasim KA, et al. Favourable outcome of non myeloablative allogeneic HSCT in adult patients with severe sickle cell disease: a single center experience of 110 patients. Blood. 2020;136:1\u20132.","journal-title":"Blood"},{"key":"2982_CR38","doi-asserted-by":"publisher","first-page":"E219","DOI":"10.1002\/ajh.26985","volume":"98","author":"V Sachdev","year":"2023","unstructured":"Sachdev V, Limerick E, Nguyen M-L, Li W, Jeffries N, Ramachandra S, et al. Cardiac effects 2 years after successful non-myeloablative human leukocyte antigen-matched related donor hematopoietic cell transplants in sickle cell disease. Am J Hematol. 2023;98:E219\u2013E221.","journal-title":"Am J Hematol"},{"key":"2982_CR39","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/bjh.12413","volume":"162","author":"S Sheth","year":"2013","unstructured":"Sheth S, Licursi M, Bhatia M. Sickle cell disease: time for a closer look at treatment options? Br J Haematol. 2013;162:455\u201364.","journal-title":"Br J Haematol"},{"key":"2982_CR40","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2117175","volume":"386","author":"J Kanter","year":"2022","unstructured":"Kanter J, Walters MC, Krishnamurti L, Mapara MY, Kwiatkowski JL, Rifkin-Zenenberg S, et al. Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N Engl J Med. 2022;386:617\u201328.","journal-title":"N Engl J Med"},{"key":"2982_CR41","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","volume":"390","author":"H Frangoul","year":"2024","unstructured":"Frangoul H, Locatelli F, Sharma A, Bhatia M, Mapara M, Molinari L, et al. Exagamglogene autotemcel for severe sickle cell disease. N Engl J Med. 2024;390:1649\u201362.","journal-title":"N Engl J Med"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02982-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02982-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02982-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:59:46Z","timestamp":1791554386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02982-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2982"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02982-2","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}